Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-
developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with …

Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells
in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal …

Morbidity and mortality associated with pediatric malignant primary brain tumors remain high
in the absence of effective therapies. Macrophage-mediated phagocytosis of tumor cells via …

Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited
treatment options. CD47 is a cell-surface molecule that promotes immune evasion by …

With the current biotherapeutic market dominated by antibody molecules, bispecific
antibodies represent a key component of the next-generation of antibody therapy. Bispecific …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …

The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine
kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted …

CD47 is an antiphagocytic signal that cancer cells employ to inhibit macrophage-mediated
destruction. Here, we modified the binding domain of human SIRPα, the receptor for CD47 …

With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age
as therapeutics, generating a market value of 11billionin2004,expectedtoreach 26 billion by …

Purpose The aim of the present paper is to review the role of HER2 antibodies, affibodies
and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including …